Related Experiment Video
Updated: Sep 17, 2025

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Clinical and health status after permanent pacemaker implantation in patients undergoing transcatheter aortic valve
Masaaki Nakase1, Daijiro Tomii1, Jonas Lanz1
1Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
Background:
The impact of new permanent pacemaker (PPM) implantation on prognosis after transcatheter aortic valve replacement (TAVR) is controversial.
Objectives:
To investigate the impact of new PPM implantation on combined outcomes of vital and patient-reported health status after TAVR.
Methods:
Patients in the SCOPE (Safety and Efficacy of the ACURATE Neo/TF Compared to the SAPIEN 3 Bioprosthesis) trial were stratified according to new PPM implantation within 30 days of TAVR. In this trial, clinical endpoints were adjudicated according to the Valve Academic Research Consortium (VARC)-2 definition. The combined outcomes, including general outcomes and clinical efficacy, were retrospectively adjudicated according to the VARC-3 definition at 1 and 3 years of follow-up.
Results:
Among 640 patients without a PPM at baseline (mean age 82.8 ± 4.1 years, 58.1 % females, mean Society of Thoracic Surgeons predicted risk of mortality 4.2 ± 2.5), 69 (10.8 %) required PPM implantation within 30 days of TAVR. Patients requiring a PPM had higher rates of right ventricular dysfunction (33 % versus 15 %, P = 0.038) at 1 year. Improvement in patient-health status measures was similar between groups throughout the study period. Patients requiring a new PPM had similar rates of unfavorable clinical outcomes (Risk ratio [RR]adjusted 0.89 [95 % CI 0.68-1.16]) and clinical efficacy (RRadjusted 0.96 [95 % CI 0.76-1.22]) compared to those who did not require new PPM implantation.
Conclusions:
In the SCOPE I trial, new PPM implantation complicating TAVR had no impact on an integrated endpoint of vital and disease-specific health status throughout 3 years of follow-up.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Aortic Regurgitation III: Medical Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Valve Prolapse II: Assessment and Management
Cardiac Catheterization II: Right Heart Catheterization

